Amicus Therapeutics News and Activities

Presence

Amicus Therapeutics develops and sells medicines for rare diseases. Its products and support services help patients, healthcare providers, and treatment centers manage long term genetic conditions.

Amicus Therapeutics products and services overview:

Rare disease therapies
Biologic medicines
Patient support services
Drug development

Revenue: ~$530 million

Employees: 500

Headquarters: Princeton, United States (USA)

Amicus Therapeutics is owned by Biomarin Pharmaceutical.

Biomarin Pharmaceutical is one of the...

Biomarin Pharmaceutical is a company listed under the stock ticker BMRN (US).

Biomarin Pharmaceutical has a direct presence in 5 countries.

Biomarin Pharmaceutical has 6 subsidiaries including Amicus Therapeutics, Amicus Therapeutics France and Amicus Therapeutics Germany.

They are in:

Biotechnology86%
Pharmaceuticals14%

Acquisition, funding and merger involving Biomarin Pharmaceutical.

Biomarin Pharmaceutical has acquired Amicus Therapeutics (posted on April 27 2026).
Biomarin Pharmaceutical has announced the acquisition of Amicus Therapeutics (posted on December 22 2025).

Executives

View the org chart displaying its 30 main executives

Most searched biographies at Amicus Therapeutics

Popular executive movements at Amicus Therapeutics

Michael Kelly, Director, has left the company (posted on April 27 2026).

Popular executive movements at Biomarin Pharmaceutical

Richard Meier, Chairman of the Board, will retire on Jun. 2, 2026 (posted on April 22 2026).
Ian Clark who is Director, will become Chairman of the Board on Jun. 2, 2026 (posted on April 22 2026).
Arpit Davé has joined the company as Chief Digital and Information Officer (posted on January 13 2026).

Create your alert
to follow the executive moves at Amicus Therapeutics.